

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 December 2023 (14.12.2023)



(10) International Publication Number
WO 2023/237512 A1

(51) International Patent Classification:

A61K 31/192 (2006.01) *A61P 9/04* (2006.01)
A61K 31/70 (2006.01) *A61P 9/12* (2006.01)
A61P 9/00 (2006.01) *A61P 13/12* (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2023/065046

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

(22) International Filing Date:

06 June 2023 (06.06.2023)

Published:

— *with international search report (Art. 21(3))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/365,969 07 June 2022 (07.06.2022) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151 85 Södertälje (SE).

(72) Inventors: **GABRIELSEN, Anders**; ASTRAZENECA AB, SE-151 85 Södertälje (SE). **PETERSEN, Daniel Tor**; ASTRAZENECA AB, SE-151 85 Södertälje (SE). **CONNOLLY, Kathleen Marie**; AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB). **UFNAL, Marcin**; AstraZeneca Pharma Poland SP. Z O.O, Postępu 14, 02-676 Warszawa (PL).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; Association 813, Eastbrook House, Shaftesbury Road, CAMBRIDGE Cambridgeshire CB2 8BF (GB).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: COMBINATIONS OF RXFP1 MODULATORS AND SGLT2 INHIBITORS

(57) Abstract: The specification generally relates to combinations of RXFP1 modulators and SGLT2 inhibitors, in particular pharmaceutical compositions comprising such combinations, and therapeutic methods using such combinations.

WO 2023/237512 A1